Department of Immunology and Allergy, Ordu University Education and Research Hospital, Ordu 52200, Türkiye.
Department of Cardiology, Haseki Training and Research Hospital, University of Health Sciences, Istanbul 34265, Türkiye.
Medicina (Kaunas). 2023 Oct 20;59(10):1869. doi: 10.3390/medicina59101869.
: Pulmonary arterial hypertension (PAH) is a rare chronic disease of the small pulmonary arteries that causes right heart failure and death. Accurate management of PAH is necessary to decrease morbidity and mortality. Understanding current practices and perspectives on PAH is important. For this purpose, we intended to determine physicians' knowledge, attitudes, and practice patterns in adult pulmonary arterial hypertension (PAH) in Turkey. : Between January and February 2022, an online questionnaire was sent via e-mail to all cardiologists and pulmonologists who were members of the Turkish Society of Cardiology (TSC) and the Turkish Thoracic Society (TTS). : A total of 200 physicians (122 pulmonologists and 78 cardiologists) responded to the questionnaire. Cardiologists were more frequently involved in the primary diagnosis and treatment of PAH than pulmonologists (37.2% vs. 23.8%, = 0.042). More than half of the physicians had access to right heart catheterization. In mild/moderate PAH patients with a negative vasoreactivity test, the monotherapy option was most preferred (82.8%) and endothelin receptor antagonists (ERAs) were the most preferred group in these patients (73%). ERAs plus phosphodiesterase-5 inhibitors (PDE-5 INH) were the most preferred (69%) combination therapy, and prostacyclin analogues plus PDE-5 INH was preferred by only pulmonologists. : Overall, clinical management of patients with PAH complied with guideline recommendations. Effective clinical management of PAH in specialized centers that having right heart catheterization achieve better outcomes.
肺动脉高压（PAH）是一种罕见的肺小动脉慢性疾病，可导致右心衰竭和死亡。准确管理 PAH 对于降低发病率和死亡率非常重要。了解当前 PAH 的实践和观点很重要。为此，我们旨在确定土耳其成人肺动脉高压（PAH）医生的知识、态度和实践模式。
在 2022 年 1 月至 2 月期间，通过电子邮件向土耳其心脏病学会（TSC）和土耳其胸科学会（TTS）的所有心脏病专家和肺科医生发送了在线问卷。
共有 200 名医生（122 名肺科医生和 78 名心脏病专家）回答了问卷。与肺科医生相比，心脏病专家更频繁地参与 PAH 的初步诊断和治疗（37.2%比 23.8%， = 0.042）。超过一半的医生可以进行右心导管检查。在血管反应性试验阴性的轻度/中度 PAH 患者中，首选单一疗法（82.8%），这些患者中内皮素受体拮抗剂（ERA）是最受欢迎的药物（73%）。ERA 加磷酸二酯酶-5 抑制剂（PDE-5 INH）是最受欢迎的（69%）联合治疗方案，只有肺科医生更喜欢前列环素类似物加 PDE-5 INH。
总体而言，PAH 患者的临床管理符合指南建议。在有右心导管检查的专门中心进行有效的 PAH 临床管理可获得更好的结果。
